CORE-005: LEUKEMIA TISSUE BANK SHARED RESOURCE (LTB) PROJECT SUMMARY / ABSTRACT The OSUCCC Leukemia Tissue Bank (LTB) is a critical resource for OSUCCC investigators, and the Leukemia Research Program, conducting translational research in hematologic malignancies. The LTB procures samples in 2 ways, via a general biobanking protocol as well as using specific clinical research protocols, collecting blood, bone marrow, leukapheresis products and others as requested. The LTB performs rapid processing of biospecimens, e.g., cell isolation and cryopreservation, assesses the quality of collected samples, delivers fresh samples or stores them for future use, provides clinical annotation for study subjects and distributes samples to investigators. Additional services available to researchers include serial collections, specialized processing, specialized specimen preparation and characterization, protocol optimization, and assistance with design of laboratory and clinical correlative studies. The LTB is a longstanding biobank, and with a >90% subject participation rate, it has collected 14,233 samples from 5,195 subjects, allowing for detailed investigations of many subtypes of hematologic cancers. Dr. Lucas is the Director of the LTB, and Dr. Bloomfield is the Senior Faculty Advisor.
The Specific Aims of the LTB are: 1) to consent subjects and procure samples from hematologic malignancy patients using state-of-the art procedures to optimally preserve the value of patient materials; 2) to uniformly process, characterize and store biospecimens; and, 3) to provide biospecimens with associated clinical, pathological and genomic data to OSUCCC researchers and to outside institutions so that they can correlate findings from patient samples with clinical or population-based outcomes. The LTB coordinates with other OSUCCC shared resources, e.g., Analytical Cytometry, Genomics, Pharmacoanalytical, and the Clinical Trials Processing Laboratory. During the last five year grant period, the LTB supported the research of 34 investigators, 30 of whom were OSUCCC members. Together, the LTB samples were used for 98 publications, of which 18 were published in journals with an impact factor >10, and 15 NCI grants. As a future direction, the facility will be expanded with OSUCCC support as required to meet researchers' needs. Working with the Genomics Shared Resource and the Bioinformatics Shared Resource, we will embark upon indexing leukemia samples based on genomic profiles. The LTB leverages extensive institutional support and seeks only 15.3% support from CCSG funds. The Leukemia Tissue Bank Shared Resource is part of the Clinical Grouping.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387

Showing the most recent 10 out of 2602 publications